National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure.

[1]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[2]  Peter C Austin,et al.  Relation between cardiac troponin I and mortality in acute decompensated heart failure. , 2007, American heart journal.

[3]  Faquan Liang,et al.  Evidence for functional heterogeneity of circulating B-type natriuretic peptide. , 2007, Journal of the American College of Cardiology.

[4]  A. Akdoğan,et al.  B-type natriuretic peptide (BNP) levels in female systemic lupus erythematosus patients: what is the clinical significance? , 2007, Clinical Rheumatology.

[5]  K. Furie,et al.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2007, Circulation.

[6]  J. Struck,et al.  Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. , 2007, Journal of cardiac failure.

[7]  G. Brabant,et al.  Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. , 2007, Clinical chemistry.

[8]  D. Phelan,et al.  The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. , 2007, Journal of cardiac failure.

[9]  M. Padeletti,et al.  Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. , 2007, Journal of the American College of Cardiology.

[10]  K. Bibbins-Domingo,et al.  N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. , 2007, JAMA.

[11]  P. Donnan,et al.  A critical re‐appraisal of different ways of selecting ambulatory patients with suspected heart failure for echocardiography , 2007, European journal of heart failure.

[12]  P. Hildebrandt,et al.  Unexplained week‐to‐week variation in BNP and NT‐proBNP is low in chronic heart failure patients during steady state , 2007, European journal of heart failure.

[13]  Jacques Pouchot,et al.  A gray zone assigned to inconclusive results of quantitative diagnostic tests: Application to the use of brain natriuretic peptide for diagnosis of heart failure in acute dyspneic patients. , 2006, Clinical chemistry.

[14]  E. Perna,et al.  Increased levels of cardiac troponin-T in outpatients with heart failure and preserved systolic function are related to adverse clinical findings and outcome , 2006, Coronary artery disease.

[15]  S. Gottlieb,et al.  B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. , 2006, American heart journal.

[16]  P. Richardson,et al.  Interactions of two monoclonal antibodies with BNP: high resolution epitope mapping using fluorescence correlation spectroscopy. , 2006, Biochemistry.

[17]  Takeshi Kimura,et al.  Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies , 2006, Heart and Vessels.

[18]  Alan H B Wu,et al.  Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. , 2006, American heart journal.

[19]  J. Struck,et al.  Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure , 2006, European journal of clinical investigation.

[20]  A. Dwyer,et al.  Influence of history of heart failure on diagnostic performance and utility of B-type natriuretic peptide testing for acute dyspnea in the emergency department. , 2006, American heart journal.

[21]  Y. Pinto,et al.  Amino-terminal pro-brain natriuretic Peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction? , 2006, Journal of the American College of Cardiology.

[22]  L. Tarantini,et al.  Changes in plasma N-terminal proBNP levels and ventricular filling pressures during intensive unloading therapy in elderly with decompensated congestive heart failure and preserved left ventricular systolic function. , 2006, Journal of cardiac failure.

[23]  S. Hazen,et al.  Plasma myeloperoxidase levels in patients with chronic heart failure. , 2006, The American journal of cardiology.

[24]  Y. Pinto,et al.  Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. , 2006, The American journal of cardiology.

[25]  C. Forleo,et al.  Prognostic value of brain natriuretic peptide in the management of patients receiving cardiac resynchronization therapy , 2006, European journal of heart failure.

[26]  C. Frampton,et al.  NTproBNP‐guided drug treatment for chronic heart failure: design and methods in the “BATTLESCARRED” trial , 2006, European journal of heart failure.

[27]  S. Yusuf,et al.  Comparative Impact of Multiple Biomarkers and N-Terminal Pro-Brain Natriuretic Peptide in the Context of Conventional Risk Factors for the Prediction of Recurrent Cardiovascular Events in the Heart Outcomes Prevention Evaluation (HOPE) Study , 2006, Circulation.

[28]  B. Pathik,et al.  Myeloperoxidase and C-reactive protein augment the specificity of B-type natriuretic peptide in community screening for systolic heart failure. , 2006, American heart journal.

[29]  M. Jessup,et al.  Stage B Heart Failure: Management of Asymptomatic Left Ventricular Systolic Dysfunction , 2006, Circulation.

[30]  C. Schindler,et al.  Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. , 2006, Archives of internal medicine.

[31]  R. Rodeheffer,et al.  Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide: Biomarkers for Mortality in a Large Community-Based Cohort Free of Heart Failure , 2006, Hypertension.

[32]  A. Hoes,et al.  Low prevalence of B-type natriuretic peptide levels < 100 pg/mL in patients with heart failure at hospital discharge. , 2006, American heart journal.

[33]  J. Hollander,et al.  Gray zone BNP levels in heart failure patients in the emergency department: results from the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) multicenter study. , 2006, American heart journal.

[34]  M. Pfisterer,et al.  Management of elderly patients with congestive heart failure--design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). , 2006, American heart journal.

[35]  C. Vergnes,et al.  Use of N-terminal prohormone brain natriuretic peptide assay for etiologic diagnosis of acute dyspnea in elderly patients. , 2006, American heart journal.

[36]  C. Frampton,et al.  Introduction of Metoprolol Increases Plasma B-Type Cardiac Natriuretic Peptides in Mild, Stable Heart Failure , 2006, Circulation.

[37]  C. Camargo,et al.  Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. , 2006, Archives of internal medicine.

[38]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[39]  R. Rodeheffer,et al.  Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. , 2006, Journal of the American College of Cardiology.

[40]  D. Lloyd‐Jones,et al.  Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. , 2006, Journal of the American College of Cardiology.

[41]  R. Doughty,et al.  Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. , 2006, Journal of the American College of Cardiology.

[42]  R. Califf,et al.  Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. , 2005, JAMA.

[43]  G. Fonarow,et al.  Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. , 2005, American heart journal.

[44]  F. Fouad-Tarazi,et al.  Blood volume and brain natriuretic peptide in congestive heart failure: a pilot study. , 2005, American heart journal.

[45]  R. Califf,et al.  Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. , 2005, American heart journal.

[46]  J. Ornato,et al.  ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult—Summary Article , 2005 .

[47]  M. Fraser,et al.  BNP-guided therapy not better than expert's clinical assessment for beta-blocker titration in patients with heart failure. , 2005, Congestive heart failure.

[48]  D. Leosco,et al.  Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. , 2005, European heart journal.

[49]  D. Arab,et al.  The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. , 2005, Journal of the American College of Cardiology.

[50]  S. Kong,et al.  Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure. , 2005, Journal of cardiac failure.

[51]  M. Chung,et al.  Preimplantation B-type natriuretic peptide concentration is an independent predictor of future appropriate implantable defibrillator therapies , 2005, Heart.

[52]  R. Woitas,et al.  N-terminal pro-B-type natriuretic peptide and mortality in coronary heart disease. , 2005, The New England journal of medicine.

[53]  C. Camargo,et al.  The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. , 2005, The American journal of cardiology.

[54]  D. Lloyd‐Jones,et al.  Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. , 2005, American heart journal.

[55]  Eduardo R Perna,et al.  Minor myocardial damage detected by troponin T is a powerful predictor of long-term prognosis in patients with acute decompensated heart failure. , 2005, International journal of cardiology.

[56]  L. Køber,et al.  N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. , 2005, The New England journal of medicine.

[57]  L. Wallentin,et al.  Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. , 2005, Journal of the American College of Cardiology.

[58]  R. Starling,et al.  B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. , 2005, American heart journal.

[59]  M. Drazner,et al.  Unexpected BNP levels in patients with advanced heart failure: a tale of caution and promise. , 2005, American heart journal.

[60]  Yigal M. Pinto,et al.  Galectin-3 Marks Activated Macrophages in Failure-Prone Hypertrophied Hearts and Contributes to Cardiac Dysfunction , 2004, Circulation.

[61]  A. Barbagelata,et al.  Ongoing Myocardial Injury in Stable Severe Heart Failure: Value of Cardiac Troponin T Monitoring for High-Risk Patient Identification , 2004, Circulation.

[62]  M. Quiñones,et al.  Optimal Noninvasive Assessment of Left Ventricular Filling Pressures: A Comparison of Tissue Doppler Echocardiography and B-Type Natriuretic Peptide in Patients With Pulmonary Artery Catheters , 2004, Circulation.

[63]  I. Squire,et al.  Plasma urocortin in human systolic heart failure. , 2004, Clinical science.

[64]  P. Hildebrandt,et al.  Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population , 2004, Heart.

[65]  Daniel Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death. , 2004, The New England journal of medicine.

[66]  M. Pfisterer,et al.  Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. , 2004, The New England journal of medicine.

[67]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[68]  James D. Thomas,et al.  Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. , 2004, Journal of the American College of Cardiology.

[69]  A. Richards,et al.  The natriuretic peptides in heart failure , 2004, Basic Research in Cardiology.

[70]  P. Hildebrandt,et al.  N‐terminal‐pro‐B‐type natriuretic peptide (NT‐pro‐BNP) in different thyroid function states , 2004, Clinical endocrinology.

[71]  F. van Lente,et al.  Plasma B-Type Natriuretic Peptide Levels in Ambulatory Patients With Established Chronic Symptomatic Systolic Heart Failure , 2003, Circulation.

[72]  M. Packer Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? , 2003, Circulation.

[73]  A. Wu,et al.  Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[74]  Motoyuki Nakamura,et al.  The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. , 2003, American journal of hypertension.

[75]  R. Doughty,et al.  Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. , 2003, Journal of the American College of Cardiology.

[76]  Stephen J. Huang,et al.  The confounding effects of age, gender, serum creatinine, and electrolyte concentrations on plasma B-type natriuretic peptide concentrations in critically ill patients* , 2003, Critical care medicine.

[77]  A. Maisel The Diagnosis of Acute Congestive Heart Failure: Role of BNP Measurements , 2003, Heart Failure Reviews.

[78]  A. Torbicki,et al.  N‐terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism , 2003, European Respiratory Journal.

[79]  I. Squire,et al.  Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate , 2003, European journal of heart failure.

[80]  T. McDonagh,et al.  N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. , 2003, European heart journal.

[81]  Euan A Ashley,et al.  Novel Role for the Potent Endogenous Inotrope Apelin in Human Cardiac Dysfunction , 2003, Circulation.

[82]  G. Merlini,et al.  Biological variation of N-terminal pro-brain natriuretic peptide in healthy individuals. , 2003, Clinical chemistry.

[83]  A. Wu,et al.  Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. , 2003, The American journal of cardiology.

[84]  F. Horkay,et al.  Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. , 2003, Biochemical and biophysical research communications.

[85]  I. Squire,et al.  Myotrophin in human heart failure. , 2003, Journal of the American College of Cardiology.

[86]  G. Fonarow,et al.  Cardiac Troponin I Is Associated With Impaired Hemodynamics, Progressive Left Ventricular Dysfunction, and Increased Mortality Rates in Advanced Heart Failure , 2003, Circulation.

[87]  D. vesely,et al.  Natriuretic peptides and acute renal failure. , 2003, American journal of physiology. Renal physiology.

[88]  I. Hisatome,et al.  Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure. , 2003, Journal of cardiac failure.

[89]  I. Squire,et al.  Pre‐discharge, but not admission, levels of NT‐proBNP predict adverse prognosis following acute LVF , 2003, European journal of heart failure.

[90]  U. Dahlström,et al.  Utility of the amino-terminal fragment of pro-brain natriuretic peptide in plasma for the evaluation of cardiac dysfunction in elderly patients in primary health care. , 2003, Clinical chemistry.

[91]  R. Califf,et al.  N‐Terminal Pro‐Brain Natriuretic Peptide and Other Risk Markers for the Separate Prediction of Mortality and Subsequent Myocardial Infarction in Patients With Unstable Coronary Artery Disease: A Global Utilization of Strategies To Open occluded arteries (GUSTO)‐IV Substudy , 2003, Circulation.

[92]  D. Levy,et al.  Heritability and Genetic Linkage of Plasma Natriuretic Peptide Levels , 2003, Circulation.

[93]  S. Mudaliar,et al.  Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. , 2003, Diabetes care.

[94]  C. Frampton,et al.  B-Type Natriuretic Peptides and Ejection Fraction for Prognosis After Myocardial Infarction , 2003, Circulation.

[95]  P. Palatini,et al.  C-reactive protein in acute myocardial infarction: association with heart failure. , 2003, American heart journal.

[96]  Richard Kamin,et al.  Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. , 2003, Journal of the American College of Cardiology.

[97]  M. Silver,et al.  High incidence of elevated B-type natriuretic peptide levels and risk factors for heart failure in an unselected at-risk population (stage A): implications for heart failure screening programs. , 2003, Congestive heart failure.

[98]  P. Hanrath,et al.  Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure. , 2003, The American journal of cardiology.

[99]  L. Fisher,et al.  Changes in Brain Natriuretic Peptide and Norepinephrine Over Time and Mortality and Morbidity in the Valsartan Heart Failure Trial (Val-HeFT) , 2003, Circulation.

[100]  J. van der Linden,et al.  Improved neurohormonal markers of ventricular function after restoring sinus rhythm by the Maze procedure. , 2003, The Annals of thoracic surgery.

[101]  J. Hollander,et al.  B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[102]  Richard T. Lee,et al.  Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker , 2003, Circulation.

[103]  S. Anker,et al.  Myocardial Production of C-Type Natriuretic Peptide in Chronic Heart Failure , 2003 .

[104]  M. Emdin,et al.  Influence of Gender on Circulating Cardiac Natriuretic Hormones in Patients with Heart Failure , 2003, Clinical chemistry and laboratory medicine.

[105]  I. Squire,et al.  Plasma Urotensin in Human Systolic Heart Failure , 2002, Circulation.

[106]  J. Herlitz,et al.  N-Terminal Pro-B-Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary Syndromes , 2002, Circulation.

[107]  C. Zanker,et al.  Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. , 2002, Journal of the American College of Cardiology.

[108]  J. Cohn,et al.  Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT) , 2002, Circulation.

[109]  D. Duprez,et al.  Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: results from the RALES neurohormonal substudy. , 2002, Journal of the American College of Cardiology.

[110]  D. Levy,et al.  Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. , 2002, JAMA.

[111]  Douglas W Mahoney,et al.  Plasma brain natriuretic peptide concentration: impact of age and gender. , 2002, Journal of the American College of Cardiology.

[112]  A. Richards,et al.  Plasma urotensin II in heart failure , 2002, The Lancet.

[113]  A. Richards,et al.  Plasma brain natriuretic peptide after long‐term treatment for heart failure in general practice , 2002, European journal of heart failure.

[114]  Alan S Maisel,et al.  Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. , 2002, The New England journal of medicine.

[115]  M. Mcmurdo,et al.  B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patients. , 2002, Age and ageing.

[116]  S. Douglas,et al.  Congestive heart failure and expression of myocardial urotensin II , 2002, The Lancet.

[117]  M. Redfield,et al.  The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. , 2002, Journal of cardiac failure.

[118]  J. Alonso-Martínez,et al.  C‐reactive protein as a predictor of improvement and readmission in heart failure , 2002, European journal of heart failure.

[119]  R. Berger,et al.  B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure , 2002, Circulation.

[120]  M. Pfeffer,et al.  Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. , 2002, Journal of the American College of Cardiology.

[121]  L. Ng,et al.  Non-competitive immunochemiluminometric assay for cardiotrophin-1 detects elevated plasma levels in human heart failure. , 2002, Clinical science.

[122]  A. DeMaria,et al.  Utility of B-Natriuretic Peptide in Detecting Diastolic Dysfunction: Comparison With Doppler Velocity Recordings , 2002, Circulation.

[123]  A. DeMaria,et al.  Utility of B-Natriuretic Peptide in Detecting Diastolic Dysfunction , 2002 .

[124]  A. Maggioni,et al.  Comparative Measurement of N-Terminal Pro-Brain Natriuretic Peptide and Brain Natriuretic Peptide in Ambulatory Patients with Heart Failure , 2002, Clinical chemistry and laboratory medicine.

[125]  M. Vogeser,et al.  Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[126]  R. Doughty,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. , 2001, Journal of the American College of Cardiology.

[127]  M. Kinoshita,et al.  Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. , 2001, Journal of the American College of Cardiology.

[128]  P. Krishnaswamy,et al.  A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. , 2001, Journal of cardiac failure.

[129]  M. Vogeser,et al.  Clinical value of brain natriuretic peptide for candidate selection before cardiac transplantation. , 2001, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[130]  L. Lenert,et al.  A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. , 2001, Journal of the American College of Cardiology.

[131]  H. Hense,et al.  Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population , 2000, Journal of hypertension.

[132]  L. Ng,et al.  Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. , 2000, Clinical science.

[133]  Y. Murakami,et al.  Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. , 2000, Journal of cardiac failure.

[134]  M. Enriquez-Sarano,et al.  Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. , 2000, Journal of the American College of Cardiology.

[135]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[136]  D. Murdoch,et al.  Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. , 1999, American heart journal.

[137]  F. Follath,et al.  Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. , 1999, American heart journal.

[138]  G. MacGregor,et al.  How does treatment influence endocrine mechanisms in acute severe heart failure? Effects on cardiac natriuretic peptides, the renin system, neuropeptide Y and catecholamines. , 1998, Clinical science.

[139]  C. Frampton,et al.  Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. , 1998, Circulation.

[140]  B. Cheung PLASMA CONCENTRATION OF BRAIN NATRIURETIC PEPTIDE IS RELATED TO DIASTOLIC FUNCTION IN HYPERTENSION , 1997, Clinical and experimental pharmacology & physiology.

[141]  A. Richards,et al.  Brain natriuretic factor: regional plasma concentrations and correlations with haemodynamic state in cardiac disease. , 1993, British heart journal.

[142]  S. Steinhubl,et al.  Risk stratification for patients undergoing nonurgent percutaneous coronary intervention using N-terminal pro-B-type natriuretic peptide: a Clopidogrel for the Reduction of Events During Observation (CREDO) substudy. , 2007, American heart journal.

[143]  K. Swedberg,et al.  Cardiac troponin I, a possible predictor of survival in patients with stable congestive heart failure. , 2005, The Canadian journal of cardiology.

[144]  A. Maisel,et al.  B-Type Natriuretic Peptide: The Level and the Drug— Partners in the Diagnosis and Management of Congestive Heart Failure , 2004 .

[145]  U. Janssens,et al.  Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. , 2004, American heart journal.

[146]  P. McCullough,et al.  Diagnostic and therapeutic utility of B-type natriuretic peptide in patients with renal insufficiency and decompensated heart failure. , 2003, Reviews in cardiovascular medicine.

[147]  D. Morrow,et al.  Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. , 2003, Reviews in cardiovascular medicine.

[148]  T. McDonagh,et al.  Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. , 2003, Journal of the American College of Cardiology.

[149]  W. Uhl,et al.  The influence of renal function on NT-proBNP levels in various disease groups. , 2003, Clinical laboratory.

[150]  Leong L. Ng,et al.  Non-competitive immunochemiluminometric assay for cardiotrophin-I detects elevated plasma levels in human heart failure , 2002 .